All In Biotech

Investigational drug · Phase 3

Zanzalintinib

Also called: XL092

Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

11

11 still active

All registered trials

47

Any phase or sponsor naming "Zanzalintinib"

First trial start

2022

Sep 7, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zanzalintinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Cancer
  • Renal Cell Carcinoma (RCC)
  • Pancreatic Neuroendocrine Tumors (pNET)
  • Extra-Pancreatic NET (epNET)
  • Hepatocellular Carcinoma (HCC)
  • Differentiated Thyroid Cancer (DTC)
  • Non-Clear Cell Renal Cell Carcinoma (nccRCC)

Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Head and neck cancer · Thyroid cancer · Oncology · Kidney and urology · Gastroenterology and liver · Endocrinology and women's health

Largest trials

Live from ClinicalTrials.gov: studies naming "Zanzalintinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 17 on PubMed

Also in development for Colorectal Cancer

  • BL-M07D1Phase 317 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma

  • TucidinostatChidamide, HBI-8000Phase 39 trials

    Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis

  • PD-1 inhibitorPhase 38 trials

    BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)

  • IBI363Phase 37 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer

  • Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

  • DarovasertibIDE 196, LXS196Phase 35 trials

    IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.